BPTH Projected Dividend Yield

Com Par $0.001 (New)/Bio-Path Holdings Inc ( NASDAQ : BPTH )

Bio-Path Holdings is a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company utilizing a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Co.'s primary drug candidate, prexigebersen, which targets growth factor receptor-bound protein 2, initially started the efficacy portion of a Phase 2 clinical trial for untreated acute myeloid leukemia patients. Co.'s second drug candidate, Liposomal Bcl-2, targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. Co.'s third drug candidate, Liposomal STAT3, targets the STAT3 protein.

20 YEAR PERFORMANCE RESULTS